ASTH Astrana Health, Inc.
$37.85
Platform & Compounding FCF 85%
Two-stage FCF DCF
Moderate · Conviction

Fair Value

Trading 23.3% below fair value

You pay $37.85
Bear $22.41
Fair $49.32
Bull $82.32
Bear $22.41 -40.8% 11% stage 1 growth, 11% discount
Fair $49.32 +30.3% 19% stage 1 growth, 11% discount
Bull $82.32 +117.5% 25% stage 1 growth, 11% discount

Key Value Driver

FCF growth rate (19% base case)

Terminal Value % of EV 46%
Implied Market Multiple 33.4x

Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $41.17 from 10 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $49.32 per share.

Warnings

Stock-based employee pay equals 172% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions